b1962
mAbexperimentalBi-specific
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2022 (NCT05650385)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06838546 | Phase 2 | Feb 24, 2025 | Tasly Pharmaceuticals, Inc., Zhejiang University |
| NCT06724263 | Phase 2 | Dec 31, 2024 | Huazhong University of Science and Technology, Tasly Pharmaceuticals, Inc. |
| NCT05650385 | Phase 1 | Dec 31, 2022 | Tasly Pharmaceuticals, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Tasly Pharmaceuticals, Inc. | For profit | 3 | 3 | 2 | 2022 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Zhejiang University | Academic/Hospital | 1 | 0 | 1 | 2025 |
3 organizations
Page 1 / 1